ImmunityBio, Inc. has announced the launch of ResQ215B, a Phase 2 clinical study evaluating a novel, chemotherapy-free and lymphodepletion-free combination immunotherapy for patients with indolent B-cell non-Hodgkin lymphoma (iNHL), including Waldenström's Macroglobulinemia. The outpatient trial investigates the use of ImmunityBio's off-the-shelf CD19-targeted high-affinity natural killer (NK) cell therapy (CD19 t-haNK) in combination with nogapendekin-alfa inbakicept (ANKTIVA®), an IL-15 superagonist, and the anti-CD20 monoclonal antibody rituximab. The regimen does not require lymphodepleting chemotherapy or inpatient hospitalization. Initial results from a chemotherapy-free cohort in Waldenström's Macroglobulinemia have been reported, with all four patients achieving clinical disease control. Two patients had complete remissions lasting at least 7 and 15 months, while the other two achieved stable disease. Further evaluation of the combination with ANKTIVA will be conducted in the ongoing Phase 2 study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260202417871) on February 02, 2026, and is solely responsible for the information contained therein.